Suppr超能文献

发酵草药配方KIOM-MA-128可保护小鼠免受葡聚糖硫酸钠诱导的急性结肠炎的侵害。

Fermented herbal formula KIOM-MA-128 protects against acute colitis induced by dextran sodium sulfate in mice.

作者信息

Kim Dong-Gun, Lee Mi-Ra, Yoo Jae-Myung, Park Kwang-Il, Ma Jin-Yeul

机构信息

Korea Medicine (KM)-Application Center, Korea Institute of Oriental Medicine, 70 Cheomdan-ro, Dong-gu, Daegu, 41062, Republic of Korea.

出版信息

BMC Complement Altern Med. 2017 Jul 5;17(1):354. doi: 10.1186/s12906-017-1855-4.

Abstract

BACKGROUND

Colitis is a well-known subtype of inflammatory bowel disease and is caused by diverse factors. Previous research has shown that KIOM-MA elicits anti-inflammatory and anti-allergic effects on various diseases. KIOM-MA-128, our novel herbal formula, was generated from KIOM-MA using probiotics to improve the therapeutic efficacy. We investigated whether KIOM-MA-128 has protective activity in a mouse model of acute colitis induced by dextran sodium sulfate (DSS).

METHODS

Colitis was induced by DSS administered to ICR mice in drinking water. KIOM-MA-128 (125 or 250 mg/kg) was orally administered once per day. The body weights of the mice were measured daily, and colonic endoscopies were performed at 5 and 8 days. Colon length as well as histological and cytokine changes were observed at the end of drug administration.

RESULTS

KIOM-MA-128 has pharmacological activity in an acute colitis model. KIOM-MA-128 reduced the loss of body weight and disease activity index (DAI) and inhibited the abnormally short colon lengths and the colonic damage in this mouse model of acute colitis. Moreover, KIOM-MA-128 suppressed pro-inflammatory cytokine expression and maintained the integrity of the tight junctions during DSS-induced colitis.

CONCLUSION

The results indicated that KIOM-MA-128 protects against DSS-induced colitis in mice and suggested that this formula might be a candidate treatment for inflammatory bowel disease (IBD).

摘要

背景

结肠炎是炎症性肠病的一种著名亚型,由多种因素引起。先前的研究表明,KIOM-MA对多种疾病具有抗炎和抗过敏作用。我们的新型草药配方KIOM-MA-128是由KIOM-MA使用益生菌制成,以提高治疗效果。我们研究了KIOM-MA-128在葡聚糖硫酸钠(DSS)诱导的急性结肠炎小鼠模型中是否具有保护活性。

方法

通过在饮用水中给ICR小鼠施用DSS来诱导结肠炎。KIOM-MA-128(125或250mg/kg)每天口服一次。每天测量小鼠体重,并在第5天和第8天进行结肠内窥镜检查。在给药结束时观察结肠长度以及组织学和细胞因子变化。

结果

KIOM-MA-128在急性结肠炎模型中具有药理活性。在该急性结肠炎小鼠模型中,KIOM-MA-128减轻了体重减轻和疾病活动指数(DAI),并抑制了异常短的结肠长度和结肠损伤。此外,KIOM-MA-128在DSS诱导的结肠炎期间抑制促炎细胞因子表达并维持紧密连接的完整性。

结论

结果表明,KIOM-MA-128可保护小鼠免受DSS诱导的结肠炎,提示该配方可能是炎症性肠病(IBD)的候选治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3e2/5499052/d4a381e9fb03/12906_2017_1855_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验